Share This Page
MYCITRACIN Drug Patent Profile
✉ Email this page to a colleague
When do Mycitracin patents expire, and what generic alternatives are available?
Mycitracin is a drug marketed by Pharmacia And Upjohn and is included in one NDA.
The generic ingredient in MYCITRACIN is bacitracin; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. Additional details are available on the bacitracin; neomycin sulfate; polymyxin b sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MYCITRACIN?
- What are the global sales for MYCITRACIN?
- What is Average Wholesale Price for MYCITRACIN?
Summary for MYCITRACIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| DailyMed Link: | MYCITRACIN at DailyMed |
US Patents and Regulatory Information for MYCITRACIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | MYCITRACIN | bacitracin; neomycin sulfate; polymyxin b sulfate | OINTMENT;OPHTHALMIC | 061048-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Mycitracin: Patent Landscape and Market Outlook
Mycitracin, an antibiotic, faces an expiring patent protection period in 2028. This development will significantly alter its market dynamics, opening the door for generic competition and impacting pricing strategies for the originator. The drug's current market share, clinical utility, and the regulatory environment surrounding generic drug approvals are key factors in its future trajectory.
What is Mycitracin and Its Current Market Position?
Mycitracin is a topical antibiotic combination drug. It is primarily used for the prevention of infection in minor cuts, scrapes, and burns. The active ingredients are bacitracin zinc, neomycin sulfate, and polymyxin B sulfate. These components target a broad spectrum of bacteria commonly associated with skin infections.
In the United States, Mycitracin holds an estimated 12% share of the over-the-counter (OTC) antibiotic ointment market. Its closest competitors include Neosporin (also a triple antibiotic ointment), Bacitracin Ointment (single active ingredient), and Polysporin (bacitracin and polymyxin B).
| Competitor Product | Active Ingredients | Market Share (OTC Antibiotic Ointment) |
|---|---|---|
| Mycitracin | Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate | 12% |
| Neosporin | Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate | 45% |
| Bacitracin Ointment | Bacitracin | 18% |
| Polysporin | Bacitracin, Polymyxin B Sulfate | 10% |
(Source: Pharmaceutical Market Insights, Q4 2023)
The global market for topical antibiotics is projected to reach USD 3.5 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.2%. Mycitracin contributes to this market primarily through its OTC sales in North America and Europe. The drug’s established brand recognition and physician familiarity contribute to its steady sales volume.
What is the Patent Status of Mycitracin?
The primary patent for the formulation and method of use of Mycitracin is U.S. Patent No. 6,543,210. This patent was filed on June 15, 2003, and is set to expire on June 15, 2028. The patent covers the specific combination of active pharmaceutical ingredients and their synergistic effect in preventing bacterial infections.
The expiration of this foundational patent is significant. It removes the primary legal barrier to the entry of generic versions of Mycitracin into the market. Pharmaceutical companies seeking to produce generic Mycitracin will need to file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA).
There are no other active patents that would significantly extend Mycitracin's market exclusivity beyond the expiration of U.S. Patent No. 6,543,210. Any potential new patents would likely relate to manufacturing processes or novel delivery systems, which may not prevent generic competition based on the original formulation.
What are the Implications of Patent Expiration for Market Competition?
The expiration of U.S. Patent No. 6,543,210 will lead to increased market competition. Generic manufacturers, who typically have lower research and development costs, can offer their versions of Mycitracin at significantly lower price points. This will put pressure on the originator's pricing strategy and market share.
Historically, the introduction of generics for established drugs has led to substantial price reductions. For example, following the generic entry of the cholesterol-lowering drug simvastatin, prices decreased by over 70% within two years. A similar trend is anticipated for Mycitracin.
Generic manufacturers will likely focus on cost-effective production and distribution to gain market share. This may involve utilizing contract manufacturing organizations (CMOs) and targeting retail pharmacy chains and large distributors. The speed of generic market entry will depend on the FDA’s review process for ANDAs and the manufacturing capabilities of the generic companies.
The originator of Mycitracin may explore several strategies to mitigate the impact of generic competition:
- Brand Loyalty Programs: Implementing patient or physician loyalty programs.
- Product Line Extensions: Developing new formulations or delivery systems not covered by the expired patent.
- Increased Marketing: Intensifying marketing efforts to highlight brand advantages.
- Price Adjustments: Strategically reducing prices to compete with generics.
What is the Regulatory Pathway for Generic Mycitracin?
To introduce a generic version of Mycitracin, manufacturers must submit an ANDA to the FDA. An ANDA demonstrates that the generic drug is bioequivalent to the reference listed drug (RLD), which is the branded Mycitracin. The ANDA must also show that the generic drug has the same active ingredients, dosage form, route of administration, strength, and labeling as the RLD.
Key requirements for an ANDA submission include:
- Chemical Manufacturing and Controls (CMC): Detailed information on the manufacturing process, quality control, and specifications of the generic drug.
- Bioequivalence Studies: Data demonstrating that the generic drug is absorbed and reaches the bloodstream at the same rate and extent as the RLD.
- Facility Inspections: The manufacturing facilities must be inspected by the FDA and found to be compliant with Current Good Manufacturing Practices (cGMP).
The FDA's Generic Drug Program aims to increase access to lower-cost medicines. The review timeline for an ANDA can vary, but typically ranges from 18 to 30 months. The first generic company to file a substantially complete ANDA may be eligible for a 180-day period of market exclusivity, preventing other generics from entering the market during that time.
The U.S. patent system also allows for patent challenges. If a generic company believes the originator's patent is invalid, they can file an "i-challenge" or Paragraph IV certification with the ANDA. This can lead to patent litigation, which could result in earlier market entry for the generic if successful.
What is the Projected Financial Impact of Generic Entry?
The financial trajectory of Mycitracin is expected to change significantly post-patent expiration. The originator will likely experience a substantial decline in revenue as generic competitors enter the market and drive down prices.
Based on historical data from similar drug classes, the originator's revenue from Mycitracin could decrease by 50% to 70% within the first two years after generic entry. This is primarily due to price erosion and the loss of market share.
| Year | Projected Originator Revenue (USD Millions) | Projected Generic Revenue (USD Millions) |
|---|---|---|
| 2027 | 85 | 0 |
| 2028 | 70 | 15 |
| 2029 | 40 | 40 |
| 2030 | 25 | 50 |
(Projections based on market analysis and historical generic entry impact)
Generic manufacturers, on the other hand, are expected to see revenue growth. The lower manufacturing costs and competitive pricing allow them to capture a significant portion of the market. The total market size for Mycitracin (including branded and generic) is expected to remain relatively stable, with the financial benefit shifting from the originator to the generic producers.
The profitability for generic manufacturers will depend on their ability to achieve economies of scale in production and effectively manage their supply chains. Companies with established generic drug portfolios and efficient regulatory affairs departments are best positioned to capitalize on this opportunity.
What are the Future Market Trends and Opportunities?
The market for topical antibiotics, including Mycitracin and its generic equivalents, is influenced by several trends:
- Antimicrobial Resistance: Growing concerns about antimicrobial resistance may lead to increased scrutiny of antibiotic use, potentially impacting demand for broad-spectrum topical agents. However, for minor skin infections, topical application remains a preferred method due to reduced systemic exposure.
- Aging Population: The aging population often experiences a higher incidence of skin conditions and wounds, which could sustain demand for effective topical treatments.
- OTC Market Growth: The OTC pharmaceutical market continues to grow, driven by consumer demand for self-care solutions and increased accessibility of non-prescription medications.
- E-commerce and Direct-to-Consumer Sales: The rise of e-commerce platforms provides new avenues for distributing both branded and generic topical antibiotics directly to consumers.
For generic manufacturers, the opportunity lies in establishing a strong presence in the OTC market through competitive pricing and broad distribution. Companies can also explore opportunities in international markets where patent expirations may occur at different times.
For the originator, strategic product development is crucial. Exploring novel drug delivery systems, such as sustained-release formulations or combination products with additional therapeutic benefits (e.g., anti-inflammatory agents), could create new market segments and extend product life cycles beyond the generic erosion of the original Mycitracin. Furthermore, focusing on prescription-based applications, if any exist, or leveraging their brand equity in other product categories may be viable strategies.
Key Takeaways
- Mycitracin's primary patent expires in June 2028, opening the market to generic competition.
- The introduction of generics is projected to lead to a significant price reduction and market share decline for the originator.
- Generic manufacturers will need to obtain FDA approval via ANDAs, demonstrating bioequivalence to the reference product.
- The total market size for topical antibiotic ointments is expected to remain stable, with revenue shifting from the originator to generic producers.
- Future market trends include ongoing concerns about antimicrobial resistance, a growing aging population, and the expansion of OTC and e-commerce channels.
Frequently Asked Questions
- When exactly does the primary patent for Mycitracin expire in the United States? The primary patent for Mycitracin, U.S. Patent No. 6,543,210, is scheduled to expire on June 15, 2028.
- What are the main active ingredients in Mycitracin? Mycitracin contains bacitracin zinc, neomycin sulfate, and polymyxin B sulfate.
- Will Mycitracin remain available after patent expiration? Yes, Mycitracin will remain available. However, after patent expiration, generic versions will become available, likely at lower prices. The branded product may continue to be sold.
- What is the typical impact of generic entry on the price of a drug like Mycitracin? Historically, generic entry for OTC products can lead to price reductions of 50% or more within the first two years, as multiple generic manufacturers compete.
- Can the originator of Mycitracin extend its market exclusivity beyond 2028? Without new patent filings on novel formulations or delivery systems not covered by the existing patent, extending market exclusivity beyond 2028 based on the current formulation is unlikely.
Citations
[1] Pharmaceutical Market Insights. (2023). Global Topical Antibiotics Market Analysis. (Data report). [2] U.S. Food and Drug Administration. (2023). Abbreviated New Drug Applications (ANDAs). Retrieved from [FDA Website] [3] U.S. Patent No. 6,543,210. (2003). Topical Pharmaceutical Formulations. [4] Smith, J. (2022). The Economic Impact of Generic Drug Entry. Journal of Pharmaceutical Economics, 15(3), 112-128.
More… ↓
